Abstract
Background: Previous studies showed that Bryostatin-1, a potent PKC modulator and alphasecretase activator, can improve cognition in models of Alzheimer’s disease (AD) with chronic (>10 weeks), intraperitoneal (i.p.) administration of the drug. We compared learning and spatial memory in the APPswe, PSEN1dE985Dbo (APP/PS1) mouse model of AD and studied the ability of acute intraperitoneal and oral Bryostatin-1 to reverse cognitive deficits in this model. Compared to wild-type (WT) mice, APP/PS1 mice showed significant delays in learning the location of a submerged platform in the Morris water maze. Bryostatin-1 was administered over a 2-week course prior to and during water maze testing. Results: Acute i.p. Bryostatin-1 administration did not improve latency to escape but oral Bryostatin-1 significantly improved memory (measured by a reduction in latency to escape). This benefit of oral Bryostatin-1 administration was most apparent during the first 3 days of testing. These findings show that: 1) Bryostatin-1 is orally active in models of learning and memory, 2) this effect can be produced in less than 2 weeks and 3) this effect is not seen with i.p. administration. We conclude that oral Bryostatin-1 represents a novel, potent and long-acting memory enhancer with future clinical applications in the treatment of human AD.
Keywords: Amyloid-beta, aging, bryoids, water maze, memory, hippocampus.
Current Alzheimer Research
Title:Acute Oral Bryostatin-1 Administration Improves Learning Deficits in the APP/PS1 Transgenic Mouse Model of Alzheimer’s Disease
Volume: 12 Issue: 1
Author(s): L.M. Schrott, K. Jackson, P. Yi, F. Dietz, G.S. Johnson, T.F. Basting, G. Purdum, T. Tyler, J.D. Rios, T.P. Castor and J.S. Alexander
Affiliation:
Keywords: Amyloid-beta, aging, bryoids, water maze, memory, hippocampus.
Abstract: Background: Previous studies showed that Bryostatin-1, a potent PKC modulator and alphasecretase activator, can improve cognition in models of Alzheimer’s disease (AD) with chronic (>10 weeks), intraperitoneal (i.p.) administration of the drug. We compared learning and spatial memory in the APPswe, PSEN1dE985Dbo (APP/PS1) mouse model of AD and studied the ability of acute intraperitoneal and oral Bryostatin-1 to reverse cognitive deficits in this model. Compared to wild-type (WT) mice, APP/PS1 mice showed significant delays in learning the location of a submerged platform in the Morris water maze. Bryostatin-1 was administered over a 2-week course prior to and during water maze testing. Results: Acute i.p. Bryostatin-1 administration did not improve latency to escape but oral Bryostatin-1 significantly improved memory (measured by a reduction in latency to escape). This benefit of oral Bryostatin-1 administration was most apparent during the first 3 days of testing. These findings show that: 1) Bryostatin-1 is orally active in models of learning and memory, 2) this effect can be produced in less than 2 weeks and 3) this effect is not seen with i.p. administration. We conclude that oral Bryostatin-1 represents a novel, potent and long-acting memory enhancer with future clinical applications in the treatment of human AD.
Export Options
About this article
Cite this article as:
Schrott L.M., Jackson K., Yi P., Dietz F., Johnson G.S., Basting T.F., Purdum G., Tyler T., Rios J.D., Castor T.P. and Alexander J.S., Acute Oral Bryostatin-1 Administration Improves Learning Deficits in the APP/PS1 Transgenic Mouse Model of Alzheimer’s Disease, Current Alzheimer Research 2015; 12 (1) . https://dx.doi.org/10.2174/1567205012666141218141904
DOI https://dx.doi.org/10.2174/1567205012666141218141904 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Emerging Therapies in Relapsing-Remitting Multiple Sclerosis
Reviews on Recent Clinical Trials Development of RNA Aptamer-Based Therapeutic Agents
Current Medicinal Chemistry Galvez-Markov Network Transferability Indices: Review of Classic Theory and New Model for Perturbations in Metabolic Reactions
Current Drug Metabolism Role of Dietary Antioxidants in Neurodegenerative Diseases: Where are We Standing?
Current Pharmaceutical Design Review of Progress in Predicting Protein Methylation Sites
Current Organic Chemistry Non-Analgesic Effects of Opioids: Management of Opioid-Induced Constipation by Peripheral Opioid Receptor Antagonists: Prevention or Withdrawal?
Current Pharmaceutical Design Pediatric Acute-onset Neuropsychiatric Syndrome and <i>Mycoplasma Pneumoniae</i> Infection: A Case Report Analysis with a Metabolomics Approach
Current Pediatric Reviews Chromatin Remodeling, DNA Damage Repair and Aging
Current Genomics A Role for the Complement System in Rheumatoid Arthritis
Current Pharmaceutical Design Genetically-Modified Human Pluripotent Stem Cells: New Hopes for the Understanding and the Treatment of Neurological Diseases?
Current Gene Therapy Small Diverse Antioxidant Functionalities for Oxidative Stress Disease Drug Discovery
Mini-Reviews in Medicinal Chemistry Autoimmune Fibrotic Adverse Reactions in One-Year Treatment with Cabergoline for Women with Prolactinoma
Endocrine, Metabolic & Immune Disorders - Drug Targets The Quest for a Tumor Suppressor Gene Phenotype
Current Molecular Medicine Novel Approaches to Study the Involvement of α7-nAChR in Human Diseases
Current Drug Targets Common Pathological Mechanisms and Risk Factors for Alzheimer’s Disease and Type-2 Diabetes: Focus on Inflammation
Current Alzheimer Research Disease Modifying Therapeutic Strategies in Alzheimers Disease Targeting the Amyloid Cascade
Current Neuropharmacology Metabolic Acidosis in Sepsis
Endocrine, Metabolic & Immune Disorders - Drug Targets A Structural Feature of the Non-Peptide Ligand Interactions with Mice Mu-Opioid Receptors
Current Computer-Aided Drug Design Distribution of Chloroaluminum Phthalocyanine in a Lipid Nano-Emulsion as Studied by Second-Derivative Spectrophotometry
Micro and Nanosystems The Impact of Alexithymia on Anxiety Disorders: a Review of the Literature
Current Psychiatry Reviews